Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is Trending

Regentis Biomaterials (RGNT) jumped 506% intraday Monday to $9.40, then dropped 9.15% to $8.54 in after-hours trading after the company withdrew its Form F-1 registration statement and scrapped a planned public offering. The Israel-based regenerative medicine firm, which develops the Gelrin platform for orthopedic tissue repair, now carries a market cap of $48.69 million.

The violent swing reflects the unusual dynamic of a small-cap biotech reversing course on equity dilution. By pulling the F-1, Regentis avoided issuing new shares that would have diluted existing holders, a move that can trigger short-term relief rallies in thinly traded names. The 506% surge suggests strong speculative interest, but the after-hours pullback and low market cap signal extreme volatility remains.